True, nabumetone alone has the body of significant gastrosparing data to corroborate its safety advantages to date. Other "new NSAIDs" claim "tolerance" (not always the same as safety); however, as we indicated, "there are limited available data to rank individual NSAID GI tract tolerability accurately...."1 But what was "new" becomes "old" as COX-II (a mitogen-inducible form of prostaglandin cyclooxygenase) NSAIDs loom on the horizon—awaiting data to corroborate their safety advantages. In the meantime, it is especially important to consider alternatives to NSAIDS, such as analgesic and topical agents and sensible pain management programs, for individuals who are at higher risk for the complications of gastropathy.
Roth SH. NSAID Gastropathy-Reply. Arch Intern Med. 1997;157(3):364. doi:10.1001/archinte.1997.00440240130027